Cite
HARVARD Citation
Jones, L. et al. (2019). Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatric blood & cancer. 66 (8), p. n/a. [Online].